Plasmapheresis

Cast Nephropathy & Plasmapheresis
Alicia Notkin
Multiple_Myeloma.ppt

Acquired Cystic Kidney Disease
Alicia Notkin
Acquired_Cystic_Renal_Disease.ppt

Molecular Mechanisms of Antidiuretic Effect of Oxytocin
Alicia Notkin
Oxytocin.ppt

Therapeutics of Autoimmune Diseases
Autoimmune_Rx_4_3_06.ppt

Clinical Pathology Conference: to plasmapheresis or not?
Bill Zaloga, DO
ToPlasmapheresisOrNot.ppt

Cold Agglutinin Disease
Daniel K. Noland MD
CAD82004.ppt

Chronic Inflammatory Polyradiculoneuropathy (CIDP)
CIDP.ppt

Blood & Blood Component Donor Selection and Collection
Bill Zaloga, D.O.
Donorselectionandcollection.ppt

Renal Disorders in Multiple Myeloma
Hematology Grand Rounds, Tom Fong, MD
Renal Disorders in Multiple Myeloma.ppt

Morbidity and Mortality Conference
Brian J. Schwender, M.D.
Morbidity and Mortality Conference.ppt

Anemia
Anemia.ppt

Cryoglobulinemia
Cryoglobulinemia.ppt

Small- Vessel Vasculitides
Small- Vessel Vasculitides.ppt

Human Lupus
Human Lupus.ppt

Coping with Changing Controlled Vocabularies
James J. Cimino, M.D., Paul D. Clayton, Ph.D.
Coping with Changing Controlled Vocabularies.ppt

Coagulation Emergencies
How to deal with/avoid a bloodbath
CoagulationEmergenciesPathology.ppt

Autoimmune Inner Ear Disease
Robert H. Stroud, M.D., Jeffery T. Vrabec, M.D.
Autoimmune-Inner-Ear.ppt

Blood Collection
Terry Kotrla, MS, MT(ASCP)
DonorBloodCollection2011.ppt

Guillain-Barre Syndrome
Lisa Rose-Jones, MD
Guillain-Barre Syndrome.ppt

Gemcitabine-induced Hemolytic Uremic Syndrome
Xiaoyi (Sherry) Hu
Gemcitabine-induced Hemolytic Uremic Syndrome.ppt
Free 200 full text articles

1. Severe hypertriglyceridaemia. Treatment with plasmapheresis.
2. An alternative treatment in hypertriglyceridemia-induced acute pancreatitis in pregnancy: Plasmapheresis.
3. Plasmapheresis leading to remission of refractory nephrotic syndrome due to fibrillary glomerulonephritis: a case report.
4. Fast and spectacular clinical response to plasmapheresis in a paediatric case of anti-NMDA encephalitis.
5. Plasmapheresis for macrophage activation syndrome and multiorgan failure as first presentation of juvenile dermatomyositis.
6. Plasmapheresis in immunologic renal disease.
7. High cut-off haemodialysis induces remission of recurrent idiopathic focal segmental glomerulosclerosis after renal transplantation but is no alternative to plasmapheresis.
8. Patients treated with plasmapheresis: a case review from University Hospital of the Canary Islands.
9. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.
10. Plasmapheresis in intensive therapy unit.
11. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
12. Plasmapheresis-induced clinical improvement in a patient with steroid-resistant nephrotic syndrome due to podocin (NPHS2) gene mutation.
13. Influence of NaCl 0.9% Infusion during Plasmapheresis on IgG Content in Plasma.
14. Effective treatment of antiphospholipid syndrome with plasmapheresis and rituximab.
15. Development of recurrent facial palsy during plasmapheresis in Guillain-Barré syndrome: a case report.
16. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
17. Human Albumin Grifols 5% in plasmapheresis: a new therapy involving beta-amyloid mobilisation in Alzheimer's disease.
18. Therapeutic plasmapheresis and experience in Alzheimer's disease.
19. Neuroimaging in Alzheimer's disease: findings in plasmapheresis with albumin.
20. Investigation of the prevalence of human parvovirus B19 DNA in Korean plasmapheresis donors.
21. Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft.
22. An experience of ABO-incompatible kidney transplantation using plasmapheresis and anti-CD20 monoclonal antibody.
23. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia.
24. Plasmapheresis in a patient with rhabdomyolysis: a case report.
25. Utility of plasmapheresis in intensive care.
26. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation.
27. Plasmapheresis as a co-treatment in acute renal failure secondary to myeloma kidney.
28. Plasmapheresis for treatment of pulmonary alveolar proteinosis.
29. eComment: Plasmapheresis for near-fatal heparin-induced thrombocytopenia.
30. Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis.
31. An alternate explanation for the decrease in pemphigus antibodies with combination treatment of double-filtration plasmapheresis and IVIg.
32. Is plasmapheresis more effective than 6-methylprednisolone pulses in the management of patients with vasculitis and severe renal involvement?.
33. Plasmapheresis in the treatment of acute disseminated encephalomyelitis.
34. Steroid induced hyperlipidemic pancreatitis and new onset diabetes mellitus. Treatment with plasmapheresis.
35. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG.
36. Tandem plasmapheresis and haemodialysis as a safe procedure in 82 patients with immune-mediated disease.
37. Surgical outcome in thymic tumors with myasthenia gravis after plasmapheresis--a comparative study.
38. Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation.
39. Acute respiratory failure in patients with Guillain-Barré syndrome and myasthenic crisis treated with plasmapheresis in the intensive care unit.
40. Acute hepatic failure in a patient with hyperthyroidism and virus B hepatitis: recovery after plasmapheresis and thyroidectomy--a case report.
41. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports.
42. Therapeutic options in an immunocompromised patient with pemphigus vulgaris: potential interest of plasmapheresis and extracorporeal photochemotherapy.
43. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies.
44. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.
45. Plasmapheresis: indications and techniques.
46. Improvement of advanced postvaccinal demyelinating encephalitis due to plasmapheresis.
47. Changes in the lymphocyte subset after double-filtration plasmapheresis.
48. Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy.
49. Therapeutic response to plasmapheresis in four cases with obsessive-compulsive disorder and tic disorder triggered by streptococcal infections.
50. Plasmapheresis and corticosteroid treatment for persistent jaundice after successful drainage of common bile duct stones by endoscopic retrograde cholangiography.
51. Clinical study of double filtration plasmapheresis for treatment of refractory myasthenia gravis.
52. Plasmapheresis in the treatment of early acute kidney allograft dysfunction.
53. Reappraisal of plasmapheresis as a supportive measure in a patient with hepatic failure after major hepatectomy.
54. Hemolysis in double-filtration plasmapheresis.
55. Combined use of plasmapheresis and antidigoxin antibodies in a patient with severe digoxin intoxication and acute renal failure.
56. Successful ABO-incompatible pediatric liver transplantation utilizing standard immunosuppression with selective postoperative plasmapheresis.
57. Plasmapheresis in amiodarone-induced hyperthyroidism.
58. Hepatitis B-related polyarteritis nodosa presenting necrotizing vasculitis in the hepatobiliary system successfully treated with lamivudine, plasmapheresis and glucocorticoid.
59. Plasmapheresis in acute disseminated encephalomyelitis.
60. Indications, adverse effects and results of plasmapheresis in critical care patients.
61. Successful ABO-incompatible liver transplantation with pre- and postoperative plasmapheresis, triple immunosuppression, and splenectomy for fulminant hepatic failure.
62. Plasmapheresis reverses all side-effects of a cisplatin overdose--a case report and treatment recommendation.
63. Application of double-filtration plasmapheresis in major ABO-incompatible unrelated bone marrow transplantation.
64. Acute disseminated encephalomyelitis treated with plasmapheresis.
65. Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis.
66. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.
67. Plasmapheresis in childhood acute disseminated encephalomyelitis.
68. Anesthesia in obstetric patient with sickle cell anemia and thalassemic trait after plasmapheresis: case report.
69. Adjunctive use of plasmapheresis and intravenous immunoglobulin therapy in sepsis: a case report.
70. Plasmapheresis in the treatment of myasthenia gravis: retrospective study of 26 patients.
71. Cutaneous ulcers with type I cryoglobulinemia treated with plasmapheresis.
72. Plasmapheresis with immunosuppressive therapy vs immunosuppressive therapy alone for rapidly progressive anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis.
73. Opsoclonus myoclonus syndrome: response to plasmapheresis.
74. Therapeutic plasmapheresis for the treatment of the thrombotic thrombocytopenic purpura-haemolytic uraemic syndromes.
75. Plasmapheresis in the treatment of septic shock.
76. Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study.
77. Current applications of plasmapheresis in clinical toxicology.
78. Plasmapheresis, GM-CSF, and alveolar proteinosis.
79. Antiphospholipid syndrome treated with prednisolone, cyclophosphamide and double-filtration plasmapheresis.
80. Use of recombinant hirudin as an anticoagulant in plasmapheresis in a patient with heparin-induced thrombocytopenia.
81. Successful treatment of pure red cell aplasia with plasmapheresis in a patient with systemic lupus erythematosus.
82. Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases.
83. Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis.
84. A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia.
85. Role of plasmapheresis in the management of acute hepatic failure in children.
86. Mixed connective tissue disease with multiple organ damage: successful treatment with plasmapheresis.
87. Hashimoto's encephalopathy responding to plasmapheresis.
88. Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mismatched second liver transplantation: salvage with plasmapheresis and prostacyclin.
89. Plasmapheresis in multifocal motor neuropathy: a case report.
90. Fulminant hepatitis A in a patient with severe hyperthyroidism: rapid recovery from hepatic coma after plasmapheresis and total thyroidectomy.
91. Anaphylactic reaction to radioimmunotherapy despite plasmapheresis to remove anti-mouse antibodies.
92. Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis.
93. Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE).
94. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre.
95. Crow-Fukase syndrome--immunoadsorption plasmapheresis effectively lowers elevated interleukin-6 concentration.
96. Efficacy of early plasmapheresis in Bickerstaff's encephalitis.
97. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis?
98. Development of facial palsy during immunoadsorption plasmapheresis in Miller Fisher syndrome: a clinical report of two cases.
99. A review of the effects of plasmapheresis on drug clearance.
100. Myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibodies -- related scleroderma renal crisis treated with double-filtration plasmapheresis.
101. Nosocomial Neisseria meningitidis sepsis as a complication of plasmapheresis.
102. Amyloid associated muscle pseudohypertrophy: amelioration of motor dysfunction with plasmapheresis and dimethylsulphoxide.
103. Autologous platelet-rich plasmapheresis: risk versus benefit in repeat cardiac operations.
104. Autologous platelet-rich plasmapheresis in repeat cardiac surgery.
105. The role of plasmapheresis in the treatment of severe lupus nephritis: a case report.
106. Evaluation of plasmapheresis on the removal of tobramycin.
107. Autologous platelet-rich plasmapheresis: risk versus benefit in repeat cardiac operations.
108. Double filtration plasmapheresis in a patient with autoimmune hepatitis-systemic lupus erythematosus overlap.
109. Immunoadsorption plasmapheresis for severe generalised myasthenia gravis.
110. Metabolic alkalosis induced by plasmapheresis in a patient with systemic lupus erythematosus.
111. Influence of therapeutic plasmapheresis on elimination of ceftiaxone.
112. Peritoneal membrane plasmapheresis.
113. Plasmapheresis in radioimmunotherapy of micrometastases: a mathematical modeling and dosimetrical analysis.
114. Severe Guillain-Barré syndrome in aged patients: the effect of plasmapheresis.
115. Plasmapheresis for lupus nephritis.
116. Systemic lupus erythematosus with sensorineural hearing loss and improvement after plasmapheresis using the double filtration method.
117. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.
118. Plasmapheresis in chronic demyelinating polyneuropathy.
119. Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy.
120. Thrombotic thrombocytopenic purpura-like syndrome associated with systemic lupus erythematosus--combined treatment with plasmapheresis and fresh frozen plasma infusion.
121. Freshly isolated and cultured human monocytes obtained by plasmapheresis kill schistosomula of Schistosoma mansoni.
122. Plasmapheresis in a case of eosinophilia-myalgia syndrome with ascending polyneuropathy.
123. The effects of plasmapheresis on thyroid hormone and plasma drug concentrations in amiodarone-induced thyrotoxicosis.
124. Study on adoptive immunotherapy in patients with renal cell carcinoma. II. Plasmapheresis with adoptive immunotherapy using LAK cells and IL-2.
125. Preoperative plasmapheresis in patients undergoing cardiac surgery procedures.
126. Plasmapheresis affects responses of slowly and rapidly adapting airway receptors to pulmonary venous congestion in dogs.
127. Plasmapheresis and fulminant acute pancreatitis?
128. Plasmapheresis and fulminant acute pancreatitis.
129. Plasmapheresis: a rational treatment for fulminant acute pancreatitis?
130. Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: analysis of retreatment following plasmapheresis.
131. Dynamics of plasma lipoproteins and lipids during double filtration plasmapheresis (DEP).
132. The effect of double filtration plasmapheresis on thyroid hormone economy and thyroid function.
133. Effects of plasmapheresis and of hypoproteinemia on lung liquid conductance in awake sheep.
134. Pleural effusion after plasmapheresis in Waldenström's macroglobulinemia.
135. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia.
136. Persistence of antibrain antibodies in cerebrospinal fluid during plasmapheresis for multiple sclerosis.
137. Role of plasmapheresis in primary biliary cirrhosis.
138. Mutilating cryoglobulinaemia rapidly improved by plasmapheresis: diagnostic features on blood film.
139. The changes in plasma lipoproteins in a case of heterozygous familial hypercholesterolemia after plasmapheresis.
140. Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange.
141. Plasmapheresis in the treatment of ventilator-dependent myasthenia gravis patients. Report of four cases.
142. Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits.
143. Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange.
144. Goodpasture's syndrome: treatment with plasmapheresis, immunosuppression, and anticoagulation.
145. Cyclic neutropenia: amplification of granulocyte oscillations by lithium and long-term suppression of cycling by plasmapheresis.
146. Internal medicine-important advances in clinical medicine: plasmapheresis as therapy.
147. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children.
148. Medical practice questions: plasmapheresis for rheumatoid arthritis.
149. Plasmapheresis in clinical medicine.
150. Plasmapheresis therapy in a patient with multiple myeloma.
151. Medical practice questions: plasmapheresis.
152. Treatment of Graves' ophthalmopathy by steroid therapy, orbital radiation therapy, plasmapheresis and thyroxine replacement.
153. Carbamylcholine modulation of E-rosette formation. Effect of plasmapheresis in myasthenia gravis.
154. Acute renal failure in dense deposit disease: recovery after plasmapheresis.
155. Effect of plasmapheresis on T anc B lymphocyte functions in patients with systemic lupus erythematosus: a double blind study.
156. Acute renal failure in dense deposit disease: recovery after plasmapheresis.
157. Partial immunologic reconstitution of a patient with acquired agammaglobulinemia: a transient phenomenon accompanying therapeutic plasmapheresis.
158. Plasmapheresis and a placebo procedure in autoerythrocyte sensitisation.
159. Effects of plasmapheresis on the course of experimental allergic neuritis in rabbits.
160. Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a pilot study.
161. Plasmapheresis in the haemolytic-uraemic syndrome in children.
162. Successful plasmapheresis in the Miller-Fisher syndrome.
163. Plasmapheresis in the haemolytic-uraemic syndrome in children.
164. Successful plasmapheresis in the Miller-Fisher syndrome.
165. Successful plasmapheresis in the Miller-Fisher syndrome.
166. Successful plasmapheresis in the Miller-Fisher syndrome.
167. Successful plasmapheresis in the Miller-Fisher syndrome.
168. Control of life-threatening bleeding by combined plasmapheresis and immunosuppressive treatment in a haemophiliac with inhibitors.
169. Myasthenic syndrome: effect of choline, plasmapheresis and tests for circulating factor.
170. Idiopathic pulmonary haemosiderosis treated by plasmapheresis.
171. Plasmapheresis with return of cryoglobulin-depleted autologous plasma (cryoglobulinpheresis) in cryoglobulinemia.
172. Immunological findings during successful treatment of HBsAg-associated polyartheritis nodosa by plasmapheresis alone.
173. Exophthalmos and pretibial myxoedema not responding to plasmapheresis.
174. Exophthalmos and pretibial myxoedema not responding to plasmapheresis.
175. Goodpasture's syndrome--effects of plasmapheresis.
176. Treatment of exophthalmos and pretibial myxoedema with plasmapheresis.
177. Plasmapheresis and severe glomerulonephritis.
178. Successful treatment of exophthalmos and pretibial myxoedema with plasmapheresis.
179. Plasma exchange and plasmapheresis.
180. Plasmapheresis.
181. Plasmapheresis.
182. Plasmapheresis in thrombotic thrombocytopenic purpura (TTP)
183. Plasmapheresis and myasthenia gravis.
184. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.
185. Serial plasmapheresis in a haemophiliac with antibodies to FVIII.
186. Plasmapheresis in systemic lupus erythematosus.
187. Continuous-flow plasmapheresis in management of severe rhesus disease.
188. Recruitment and plasmapheresis of donors to provide human antitetanus immunoglobulin.
189. Proceedings: The therapeutic use of plasmapheresis in an immune complex disease.
190. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis.
191. Modification of xenograft response by selective plasmapheresis.
192. The plasmapheresis of hyperimmunized horses.
193. Selective plasmapheresis in dogs for delay of heterograft response.
194. Effects of intensive plasmapheresis on normal blood donors.
195. Comparison of the effect of plasmapheresis and penicillamine on the level of circulating rheumatoid factor.
196. Metabolic balance study of plasmapheresis in a case of Waldenstrom's macroglobulinemia.
197. Repeated plasmapheresis of blood donors as a source of platelets.
198. Effects of plasmapheresis on albumin pools in rabbits.
199. Depletion of reserve protein from extravascular extracellular fluid; C14 labeling of plasma proteins in dogs after plasmapheresis.
200. Use of plasmapheresis in blood donors.